Literature DB >> 8399492

Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype.

Y Zhang1, T Mukhopadhyay, L A Donehower, R N Georges, J A Roth.   

Abstract

A retroviral vector system was developed to transduce a K-ras antisense construct efficiently into human cancer cells. A 2-kb fragment of K-ras gene DNA in antisense orientation was linked to a beta-actin promoter and inserted into retroviral vector LNSX in two different orientations. The constructs were transfected into amphotropic packaging cell line GP+envAm12 followed by alternating transduction between the ecotropic packaging cell line psi-2 and GP+envAm12. Titers up to 9.7 x 10(7) colony-forming units (cfu)/ml were achieved without detectable replication-competent virus. The human large cell lung carcinoma cell line H460a, which has a homozygous codon 61 K-ras mutation, was transduced with an efficiency of 95% after five to seven repeated transductions. DNA polymerase chain reaction (PCR) and genomic DNA Southern blot analysis showed that the retroviral construct was integrated into the genome of H460a cells. K-ras antisense RNA expression was detected in the cells by Northern analysis, slot blot hybridization, and reverse transcriptase-PCR. Translation of the mutated K-ras p21 protein RNA was specifically inhibited, whereas expression of other p21 species was unchanged. Proliferation of H460a cells was suppressed 10-fold following transduction by the antisense construct. Colony formation in soft agarose and tumorigenicity in an orthotopic lung cancer model in nu/nu mice were dramatically reduced in H460a cells expressing antisense K-ras. We conclude that an antisense construct for K-ras can be expressed effectively in a retroviral vector that can efficiently transduce human cancer cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8399492     DOI: 10.1089/hum.1993.4.4-451

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  12 in total

Review 1.  Gene therapy in lung cancer.

Authors:  S G Swisher; J A Roth
Journal:  Curr Oncol Rep       Date:  2000-01       Impact factor: 5.075

Review 2.  Gene therapy for respiratory diseases: potential applications and difficulties.

Authors:  E W Alton; D M Geddes
Journal:  Thorax       Date:  1995-05       Impact factor: 9.139

Review 3.  New therapeutic approaches based on gene transfer techniques.

Authors:  H Chong; R G Vile
Journal:  Springer Semin Immunopathol       Date:  1996

4.  Loss-of-function genetics in mammalian cells: the p53 tumor suppressor model.

Authors:  A Carnero; J D Hudson; G J Hannon; D H Beach
Journal:  Nucleic Acids Res       Date:  2000-06-01       Impact factor: 16.971

Review 5.  Antisense oncogene and tumor suppressor gene therapy of cancer.

Authors:  W W Zhang
Journal:  J Mol Med (Berl)       Date:  1996-04       Impact factor: 4.599

Review 6.  Potential applications of gene therapy in the patient with cancer.

Authors:  P W Szlosarek; A G Dalgleish
Journal:  Drugs Aging       Date:  2000-08       Impact factor: 3.923

7.  Generation of a ribozyme-adenoviral vector against K-ras mutant human lung cancer cells.

Authors:  Y A Zhang; J Nemunaitis; A W Tong
Journal:  Mol Biotechnol       Date:  2000-05       Impact factor: 2.695

8.  Ribozyme as an approach for growth suppression of human pancreatic cancer.

Authors:  H Kijima; K J Scanlon
Journal:  Mol Biotechnol       Date:  2000-01       Impact factor: 2.695

Review 9.  Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.

Authors:  Pascale Tomasini; Preet Walia; Catherine Labbe; Kevin Jao; Natasha B Leighl
Journal:  Oncologist       Date:  2016-11-02

10.  Requirement for MUC5AC in KRAS-dependent lung carcinogenesis.

Authors:  Alison K Bauer; Misha Umer; Vanessa L Richardson; Amber M Cumpian; Anna Q Harder; Nasim Khosravi; Zoulikha Azzegagh; Naoko M Hara; Camille Ehre; Maedeh Mohebnasab; Mauricio S Caetano; Daniel T Merrick; Adrie van Bokhoven; Ignacio I Wistuba; Humam Kadara; Burton F Dickey; Kalpana Velmurugan; Patrick R Mann; Xian Lu; Anna E Barón; Christopher M Evans; Seyed Javad Moghaddam
Journal:  JCI Insight       Date:  2018-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.